Evidence map›Paper›PMID 37131784›Full record

ArticlebioRxiv : the preprint server for biology2023

Loss-of-function mutation in Omicron variants reduces spike protein expression and attenuates SARS-CoV-2 infection.

Michelle N Vu, R Elias Alvarado, Dorothea R Morris, Kumari G Lokugamage, Yiyang Zhou, Angelica L Morgan, Leah K Estes, Alyssa M McLeland, Craig Schindewolf, Jessica A Plante and 10 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 21 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 1 institution in 1 country.

Michelle N VuMicrobiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States.
R Elias AlvaradoMicrobiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States.
Dorothea R MorrisMicrobiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States.
Kumari G LokugamageMicrobiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States.
Yiyang ZhouBiochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, United States.
Angelica L MorganPathology, University of Texas Medical Branch, Galveston, TX, United States.
Leah K EstesMicrobiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States.
Alyssa M McLelandMicrobiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States.
Craig SchindewolfMicrobiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States.
Jessica A PlanteMicrobiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States.
Yani P AhearnMicrobiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States.
William M MeyersPathology, University of Texas Medical Branch, Galveston, TX, United States.
Jordan T MurrayMicrobiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States.
Patricia A Crocquet-ValdesPathology, University of Texas Medical Branch, Galveston, TX, United States.
Scott C WeaverMicrobiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States.
David H WalkerPathology, University of Texas Medical Branch, Galveston, TX, United States.
William K RussellBiochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, United States.
Andrew L RouthBiochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, United States.
Kenneth S PlanteMicrobiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States.
Vineet MenacheryMicrobiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States.
The University of Texas Medical Branch at Galveston · US

Funding

World Reference Center for Emerging Viruses and Arboviruses (WRCEVA)R24AI120942 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI WEAVER, SCOTT C · 2016 to 2024
$8.5M
Biodefense Training ProgramT32AI060549 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI ASHOK K CHOPRA, Janice J Endsley · 2004 to 2026
$3.0M
Identifying host and viral correlates for coronavirus pathogenesisR01AI153602 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI JOHNSON, BRYAN A · 2020 to 2023
$2.0M
The Host Genetics of Age-Dependent SusceptibilityR21AI145400 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI MENACHERY, VINEET D · 2020 to 2021
$451k
NIAID NIH HHS R01 AI153602NIAID NIH HHS R21 AI145400NIAID NIH HHS R24 AI120942NIAID NIH HHS T32 AI060549
6 · The paper itself

Abstract

SARS-CoV-2 Omicron variants emerged in 2022 with >30 novel amino acid mutations in the spike protein alone. While most studies focus on receptor binding domain changes, mutations in the C-terminus of S1 (CTS1), adjacent to the furin cleavage site, have largely been ignored. In this study, we examined three Omicron mutations in CTS1: H655Y, N679K, and P681H. Generating a SARS-CoV-2 triple mutant (YKH), we found that the mutant increased spike processing, consistent with prior reports for H655Y and P681H individually. Next, we generated a single N679K mutant, finding reduced viral replication

Identifiers

PMID37131784
PMCPMC10153209
OpenAlexW4366339089

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.